Abstract
Chemotherapy regimens similar to those used for non-Hodgkin’s lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success. In a recent trial, patients with intermediate or high-grade NHL were randomized to either low-dose chemotherapy with methotrexate, bleomycin, doxorubicin, vincristine and dexamethasone (m-BACOD) or to standard-dose m-BACOD with sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF). With low-dose m-BACOD 41% of patients achieved a complete remission and the median survival was 35 weeks. With standard-dose m-BA-COD and sargramostim, the percentage of complete remissions was 52% with a median survival of 31 weeks (P = n.s.). Myelosuppression was greater with standard-dose chemotherapy. In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts <100/mm3 and stage III/IV disease. In an analysis using the proportional hazards model, a “favorable” group was defined by patients with 0 or 1 adverse factor (median survival 46 weeks, survival at 144 weeks 29.5%) as compared with an unfavorable group with 3 or 4 adverse factors (median survival 18 weeks, survival at 144 weeks 0). The outcome of these patients may be improving with the use of highly active antiretroviral therapy (HAART), which seems to improve immune function and tolerance of chemotherapy. A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar respon.se rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir). There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts. Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt’s lymphomas with or without HIV infection. With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kaplan LD, Abrams DI, Feigal E et al (1989) AIDS-associated non-Hodgkin’s lymphoma in San Francisco. JAMA 261:719–724
Knowles DM, Chamulak GA, Subar M et al (1988) Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981–1986). Ann Intern Med 108:744–753
Lowenthal DA, Straus DJ, Campbell SW et al (1988) AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 61:2325–2337
Levine AM, Wernz JC, Kaplan L et al (1991) Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 266:84–88
Gill PS, Levine AM, Krailo M et al (1987) AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 5:1322–1328
Kaplan L, Straus D, Testa M et al (1997) Low-dose compared with standarddose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. N Engl J Med 336:1641–1648
Sparano JA, Wiernik PH, Hu X et al (1996) Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma. J Clin Oncol 14:3026–3035
Sparano JA, Lee S, Henry DH et al (2000) Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin’s lymphoma: a review of the Einstein, Aviano, and ECOG experience in 182 patients (abstract S15). J AIDS 23:A11
Vaccher E, Tirelli U, Soina M et al (1996) Age and serum lactic dehydrogenase level are independently prognostic factors in human immunodeficiency virus-related non-Hodgkin’s lymphomas: a single institute study of 96 patients. J Clin Oncol 14:2217–2223
Straus DJ, Huang J, Testa MA et al (1998) Prognostic factors in the treatment of HIV-associated non-Hodgkin lymphoma: analysis of AIDS Clinical Trials Group 142 — low-dose versus standard-dose m-BACOD plus granulocytemacrophage colony-stimulating factor. J Clin Oncol 16:3601–3606
Thiessard F, Morlat P, Marimoutou C et al (2000) Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodefi-ciency virus. Aquitaine cohort, France, 1986–1997. Cancer 88:1692–1702
Gisselbrecht C, Oksenhendler E, Tirelli U et al (1993) Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 95:188-196 13. Straus DJ, Wong GY, Liu J et al (1991) Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt’s type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am I Med 90:328–337
Spina M, Tirelli U, Zagonel V et al (1998) Burkitt’s lymphoma in adults with and without human immunodeficiency virus infection, a single-institut ion clinicopathologic study of 75 patients. Cancer 82:766–774
Wang ES, Straus DL Qin I et al (2000) Intensive chemotherapy (CODOX-M/ IVAC) compares favorably with other regimens for HIV positive and negative patients with Burkitt’s lymphoma (BL) (abstract). Blood 96 11:139a
Ratner L, Lee L Tang S et al (2001) Chemotherapy for human immunodeficiency associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171–2178
Avilés A, Halbe H (1999) Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma. Cancer Biother Radiopharmacol 14:349–352
Little RR Pearson D, Gutierrez M, Steinberg S et al (2000) Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin’s lymphoma (HIV-NHL) (abstract). J AIDS 23:A11
Molina A, Krishnan AY, Nademanee A et al (2000) High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 89:680–689
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Straus, D.J. (2002). Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive